Creative Medical claims 93% response rate in Ultrasome knee OA pilot
Creative Medical Technology Holdings (NASDAQ: CELZ) has announced results from a pilot study of Ultrasome, its proprietary cell-free regenerative therapy for knee osteoarthritis, reporting that 93% of participants showed clinically meaningful improvements in mobility and pain reduction. The Phoenix-based company said no serious adverse events were recorded and that the therapy was well-tolerated across the cohort.
The company did not disclose the number of patients enrolled, the study design, the duration of follow-up, or whether the pilot was randomised or controlled. Without those parameters, the headline response rate cannot be contextualised against standard-of-care comparators or competing regenerative approaches.
The platform connection
Ultrasome is derived from CELZ-201 (Olastrocel), Creative Medical's cell-based biologic currently under evaluation in its FDA-cleared ADAPT clinical trial. The company is positioning Ultrasome as a cell-free extension of that platform: by isolating the biological signalling components of CELZ-201 and delivering them without the cells themselves, it argues the product can be manufactured at scale, stored off-the-shelf, and administered in outpatient settings at lower cost.
Timothy Warbington, president and chief executive, described the development as "a significant evolution of our platform," adding that the cell-free format improves both scalability and accessibility. The company's stated next steps include expanding clinical execution of the Ultrasome programme, generating additional data, and evaluating commercialisation and partnership pathways — though no timelines or specific trial structures were provided.
Market context and competitive landscape
Osteoarthritis of the knee represents a sizeable and genuinely underserved indication. The condition affects tens of millions of adults in the United States alone, and current standard-of-care options — analgesics, corticosteroid injections, hyaluronic acid viscosupplementation, and ultimately joint replacement — address symptoms rather than the underlying degenerative process. That therapeutic gap has attracted considerable investment in biologic and regenerative approaches.
The cell-free or exosome-derived regenerative space, however, is contested and faces meaningful regulatory uncertainty. The FDA has in recent years issued warning letters to clinics marketing exosome products without approved biologics licences, and the agency's position on exosome-based therapies remains an evolving area of guidance. Creative Medical's claim that Ultrasome is derived from a GMP-manufactured, FDA-cleared trial asset is therefore commercially important: it attempts to anchor the product in an established regulatory pathway rather than the grey-market exosome category. Whether that framing will hold under closer regulatory scrutiny is a question investors should monitor.
A number of other clinical-stage companies and academic groups are pursuing extracellular vesicle and secretome-based approaches for musculoskeletal indications. The field has generated promising preclinical data, but peer-reviewed, randomised clinical evidence at meaningful scale remains limited across the sector — making Creative Medical's pilot results difficult to benchmark without the full dataset.
The company is listed on NASDAQ and characterises itself as clinical-stage; its market capitalisation remains small relative to the indication size it is targeting. Analysts and prospective partners will be looking for a controlled study design, a defined regulatory filing pathway, and partnership terms before drawing commercial conclusions from the pilot readout.